2025 North America Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report
Description
The 2025 North America Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy (CGT) Manufacturing Services Market in North America are Lonza Group, Thermo Fisher Scientific, Catalent Inc., and WuXi Advanced Therapies. Lonza leads with 14-17% market share, operating a viral vector facility in Massachusetts and expanding commercial production of allogeneic cell therapies through automated systems. Thermo Fisher holds 11-14%, offering integrated manufacturing equipment including systems for high-purity T-cell separation and lentiviral production. Catalent (9-12%) focuses on viral vectors, plasmid DNA production, and turnkey services for rare diseases, with a Maryland GMP-grade facility. WuXi (7-10%) enhances lentiviral and AAV vector capacity and uses AI-driven digital twin systems for process optimization.
These companies benefit from North America’s dominant position in the CGT market, driven by extensive biotech infrastructure, regulatory support, and rising FDA approvals of CGT products. The U.S. government is fostering access through initiatives like the 2025 Cell and Gene Therapy Access Model. Investments from private and public sectors fuel expansion of manufacturing capabilities, supporting increasing demand for scalable, cost-effective, and patient-centric therapies. Additionally, companies like Fujifilm Diosynth Biotechnologies contribute with flexible, single-use bioreactor solutions and large-scale biomanufacturing facilities in the U.S., reinforcing North America's leadership in CGT manufacturing services.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy (CGT) Manufacturing Services Market in North America are Lonza Group, Thermo Fisher Scientific, Catalent Inc., and WuXi Advanced Therapies. Lonza leads with 14-17% market share, operating a viral vector facility in Massachusetts and expanding commercial production of allogeneic cell therapies through automated systems. Thermo Fisher holds 11-14%, offering integrated manufacturing equipment including systems for high-purity T-cell separation and lentiviral production. Catalent (9-12%) focuses on viral vectors, plasmid DNA production, and turnkey services for rare diseases, with a Maryland GMP-grade facility. WuXi (7-10%) enhances lentiviral and AAV vector capacity and uses AI-driven digital twin systems for process optimization.
These companies benefit from North America’s dominant position in the CGT market, driven by extensive biotech infrastructure, regulatory support, and rising FDA approvals of CGT products. The U.S. government is fostering access through initiatives like the 2025 Cell and Gene Therapy Access Model. Investments from private and public sectors fuel expansion of manufacturing capabilities, supporting increasing demand for scalable, cost-effective, and patient-centric therapies. Additionally, companies like Fujifilm Diosynth Biotechnologies contribute with flexible, single-use bioreactor solutions and large-scale biomanufacturing facilities in the U.S., reinforcing North America's leadership in CGT manufacturing services.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
